Details

As we step into the new year, wellness and innovation take center stage. Korea's rapidly advancing medical and biotechnology industries are reshaping how people pursue healthier, longer, and more connected lives—spanning AI-enabled diagnostics, precision medicine, global clinical collaboration, and wellness tourism.

Join us for a timely discussion with William Ban (Himedi), Taesoo Sean Kim (IceMiller), and Ken Nesmith (Lunit) spotlighting Korea's health-tech startups, scale-ups, and leading institutions at the forefront of medical innovation. The conversation will explore where Korean startups are creating value across the healthcare continuum, how they are partnering with U.S. healthcare systems, investors, and regulators, and what these cross-border collaborations mean for the future of patient care, precision medicine, and wellness-driven industries.

 

This program is supported by Hanwha Life

 

Sign Up Here to Attend In-Person

 

Sign Up Here to Receive the Viewing Link

 

 

New Year, New You! Powered by K-Health

Thursday, January 22, 2026 | 6:00 PM (EST)


 The Korea Society
350 Madison Avenue, 24th Floor
New York, NY 10017

 

 

About the Speakers:

 

William Ban, COO, Himedi
William Ban is Co-Founder & COO of Himedi, a healthcare platform bridging global patients with Korea’s advanced medical and wellness ecosystem. With a focus on patient experience innovation, William works at the intersection of healthcare, technology, and global mobility - helping modernize how people access diagnostics, preventive care, and specialized treatments across borders. Through Himedi, he collaborates with leading Korean hospitals and clinics to translate Korea’s rapid advances in medical technology, bio-innovation, and wellness into seamless, trusted experiences for U.S. and international patients.

 

 

Taesoo Sean Kim, Partner, IceMiller
TaeSoo Sean Kim is a partner in Ice Miller’s Business Group and co-chair of the firm’s Asia-Pacific Practice Group. Sean represents biotechnology, pharmaceutical, and technology companies in commercial transactions, licensing, mergers and acquisitions, and other strategic business matters.

With a focus in emerging technologies, Sean negotiates complex technology licenses, collaboration agreements, and commercial contracts across fields such as drug discovery, small molecules, cell and gene therapies, artificial intelligence (AI), cryptography, lithium batteries, and other innovative technologies. As a registered patent attorney with a focus on business transactions, he provides strategic guidance on intellectual property (IP) development, IP portfolio management, and IP commercialization to both startups and established companies.

In his role as co-chair of the Asia-Pacific Practice Group, Sean serves as a relationship partner to Asia-based clients in cross-border transactions and disputes, including M&A, joint ventures, commercial agreements, and IP matters. He also leads efforts on large-scale economic development projects, such as lithium battery manufacturing and recycling plants, overseeing site selection, incentives, real estate, and regulatory compliance.

Sean is deeply involved in the startup community, having served on the Board of Korean Startups and Entrepreneurs. He currently serves as outside general counsel to startups, guiding them from pre-funding to multiple rounds of venture financing and exit.

 

 

Ken Nesmith, Group Head - Oncology, Lunit
Ken brings over 15 years of experience in healthcare and life sciences. He cofounded Lexent Bio, serving as CEO until its acquisition by Foundation Medicine, and previously led product strategy at Counsyl. His career also includes roles at Noom, BCG, and Codon Devices. Ken holds a BS from MIT and an MBA from Wharton, and today leads the Lunit Oncology Group.